Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Gary J. Nabel"'
Autor:
Cheng Cheng, LingShu Wang, Jason G. D. Gall, Martha Nason, Richard M. Schwartz, M. Juliana McElrath, Steven C. DeRosa, John Hural, Lawrence Corey, Susan P. Buchbinder, Gary J. Nabel
Publikováno v:
PLoS ONE, Vol 7, Iss 5 (2012)
Externí odkaz:
https://doaj.org/article/7c4c1402cece4c65bebe6bad0a4deed3
Autor:
Srinivas Rao, Wing-Pui Kong, Chih-Jen Wei, Zhi-Yong Yang, Martha Nason, Darrel Styles, Louis J. DeTolla, Aruna Panda, Erin M. Sorrell, Haichen Song, Hongquan Wan, Gloria C. Ramirez-Nieto, Daniel Perez, Gary J. Nabel
Publikováno v:
PLoS ONE, Vol 3, Iss 9 (2008)
Externí odkaz:
https://doaj.org/article/5e9de23408dd4fb7954297ffea5b1103
Autor:
Bradford Elmer, Errin Roberts, Susan Ryan, Lei Guo, Kurt Swanson, Maria-Carmen Obinu, Dinesh S. Bangari, Pascal Barneoud, Peter A. Piepenhagen, Laurent Pradier, Gary J. Nabel, Bailin Zhang, Tatyana V. Taksir, Zhi Yong Yang
Publikováno v:
PLoS ONE, Vol 14, Iss 12, p e0226245 (2019)
PLoS ONE
PLoS ONE
Antibody therapies for Alzheimer's Disease (AD) hold promise but have been limited by the inability of these proteins to migrate efficiently across the blood brain barrier (BBB). Central nervous system (CNS) gene transfer by vectors like adeno-associ
Autor:
John R. Mascola, Barney S. Graham, Laura Novik, Adrian B. McDermott, Richard A. Koup, Eleanor Wilson, Michelle C. Crank, Cynthia S. Hendel, Robert T. Bailer, Mary E. Enama, Julie E. Ledgerwood, Wenjuan Gu, Martha Nason, Gary J. Nabel, Vrc Study Team
Publikováno v:
PLoS ONE
PLoS ONE, Vol 11, Iss 11, p e0166393 (2016)
PLoS ONE, Vol 11, Iss 11, p e0166393 (2016)
Background VRC 012 was a Phase I study of a prototype recombinant adenoviral-vector serotype-35 (rAd35) HIV vaccine, the precursor to two recently published clinical trials, HVTN 077 and 083. On the basis of prior evaluation of multiclade rAd5 HIV va
Autor:
M. Juliana McElrath, Susan P. Buchbinder, Ling Shu Wang, Steven C. DeRosa, Cheng Cheng, Gary J. Nabel, John Hural, Martha Nason, Richard M. Schwartz, Jason G. D. Gall, Lawrence Corey
Publikováno v:
PLoS ONE, Vol 7, Iss 4, p e33969 (2012)
PLoS ONE
PLoS ONE
Background: The Step trial raised the possibility that uncircumcised men with pre-existing Ad5 neutralizing antibodies carried an increased risk of HIV infection after vaccination. Thus, understanding Ad seropositivity in humans is important to the d
Autor:
Richard A Koup, Mario Roederer, Laurie Lamoreaux, Jennifer Fischer, Laura Novik, Martha C Nason, Brenda D Larkin, Mary E Enama, Julie E Ledgerwood, Robert T Bailer, John R Mascola, Gary J Nabel, Barney S Graham, VRC 009 Study Team, VRC 010 Study Team
Publikováno v:
PLoS ONE, Vol 5, Iss 2, p e9015 (2010)
PLoS ONE
PLoS ONE
Background Induction of HIV-1-specific T-cell responses relevant to diverse subtypes is a major goal of HIV vaccine development. Prime-boost regimens using heterologous gene-based vaccine vectors have induced potent, polyfunctional T cell responses i
Autor:
Wing Pui Kong, Srinivas S. Rao, Martha Nason, Neal Van Hoeven, J. Patrick Gorres, Terrence M. Tumpey, Hanne Andersen, Chih Jen Wei, Gary J. Nabel
Publikováno v:
PLoS ONE, Vol 5, Iss 3, p e9812 (2010)
PLoS ONE
PLoS ONE
Efforts to develop a broadly protective vaccine against the highly pathogenic avian influenza A (HPAI) H5N1 virus have focused on highly conserved influenza gene products. The viral nucleoprotein (NP) and ion channel matrix protein (M2) are highly co
Autor:
Zhi Yong Yang, Srinivas S. Rao, Louis J. DeTolla, Daniel R. Perez, Gary J. Nabel, Chih-Jen Wei, Wing-Pui Kong, Gloria Ramirez-Nieto, Aruna Panda, Erin M. Sorrell, Hongquan Wan, Darrel Styles, Haichen Song, Martha Nason
Publikováno v:
PLoS ONE, Vol 3, Iss 6, p e2432 (2008)
PLoS ONE
PLoS ONE
Background Sustained outbreaks of highly pathogenic avian influenza (HPAI) H5N1 in avian species increase the risk of reassortment and adaptation to humans. The ability to contain its spread in chickens would reduce this threat and help maintain the
Autor:
Michelle C Crank, Ingelise J Gordon, Galina V Yamshchikov, Sandra Sitar, Zonghui Hu, Mary E Enama, LaSonji A Holman, Robert T Bailer, Melissa B Pearce, Richard A Koup, John R Mascola, Gary J Nabel, Terrence M Tumpey, Richard M Schwartz, Barney S Graham, Julie E Ledgerwood, VRC 308 Study Team
Publikováno v:
PLoS ONE
PLOS ONE
PLoS ONE, Vol 10, Iss 4, p e0123969 (2015)
PLOS ONE
PLoS ONE, Vol 10, Iss 4, p e0123969 (2015)
Background A novel, swine-origin influenza A (H1N1) virus was detected worldwide in April 2009, and the World Health Organization (WHO) declared a global pandemic that June. DNA vaccine priming improves responses to inactivated influenza vaccines. We
Autor:
Mary E Enama, Julie E Ledgerwood, Laura Novik, Martha C Nason, Ingelise J Gordon, LaSonji Holman, Robert T Bailer, Mario Roederer, Richard A Koup, John R Mascola, Gary J Nabel, Barney S Graham, VRC 011 Study Team
Publikováno v:
PLoS ONE, Vol 9, Iss 3, p e91366 (2014)
PLoS ONE
PLoS ONE
Background Phase 1 evaluation of the VRC HIV DNA and rAd5 vaccines delivered intramuscularly (i.m.) supported proceeding to a Phase 2 b efficacy study. Here we report comparison of the i.m., subcutaneous (s.c.) and intradermal (i.d.) routes of admini